Luxottica Group : In horizontal mouvement
Entry price | Target | Stop-loss | Potential |
---|
€27.33 |
€0 |
€0 |
-100% |
---|
Luxottica is luxury Italian brand specialized in design, manufacture, distribute of eyeglass frames and sunglasses. Products are sold under its own brands as Ray ban, Oakley and Persol and under licenses, especially Giorgio Armani, Chanel and Moschino. The share is listed both on Milan stock exchange and New York stock exchange.
The full year report 2011 showed interesting numbers. In fact company’s revenues rose more than 7% against one year previous, to $6.2 milliard, with net income up 12% to $452 million. The largest market remains North America with 58% of revenues, and then Europe (20%) and Asia (12.5%). Thomson Reuters’ consensus has recently revised upward the earnings per share estimates for 2012 and 2013 financial years.
The share during 2011 outperformed FTSE MIB 30 (Italian Index composed by the 30 largest companies in the country), underlining the defensive character of luxury sector. The same dynamic is persisted in 2012, when the share gained more than 20% while the Italian index remains almost stable. Since February the share is trading in neutral range with consolidation horizontal phase. We suggest to give attention the breakout of this range and could lead the share to historical highest near to EUR 30.
The content herein constitutes a general investment recommendation, prepared in accordance with provisions aimed at preventing market abuse by Surperformance, the publisher of MarketScreener.com. More specifically, this recommendation is based on factual elements and expresses a sincere, complete, and balanced opinion. It relies on internal or external data, considered reliable as of the date of their release. Nevertheless, this information, and the resulting recommendation, may contain inaccuracies, errors, or omissions, for which Surperformance cannot be held responsible. This recommendation, which in no way constitutes investment advice, may not be suitable for all investor profiles. The reader acknowledges and accepts that any investment in a financial instrument involves risks, for which they assume full responsibility, without recourse against Surperformance. Surperformance commits to disclosing any conflict of interest that may affect the objectivity of its recommendations.